Industry Groups Push CMS To Pay For Algorithms In Multi-Analyte Tests
This article was originally published in The Gray Sheet
Executive Summary
The agency’s proposal not to separately pay for the algorithmic analysis that forms the basis of many multi-analyte molecular diagnostic tests misconstrues the nature of the tests, industry groups argue. They call for a final determination by CMS that more truly reflects the value of these assays.
You may also be interested in...
MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes
Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as their concerns about perceived changes to the gap-fill regulation.
MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes
Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.
CMS In Brief
Latest news from the Medicare agency includes updates from the physician fee schedule and clinical laboratory fee schedule, an American Hospital Association lawsuit, and more.